
Please try another search
By Sam Boughedda
Goodrx Holdings Inc (NASDAQ:GDRX) shares jumped over 17% Thursday after Citi analysts initiated a Buy/High-Risk rating and $7 price target on the stock.
The analysts said demand for the company's services should overcome near-term headwinds. However, he also acknowledged that "in a rational healthcare market, GDRX would not exist."
"It feeds off the exhaust of a complex and opaque drug distribution channel which, in our view, disadvantages patients. That said, we do not see the irrationality/complexity/opacity of drug distribution abating any time soon," said the analysts. "In our view, GDRX will continue to serve a vital role in bringing transparency/consumerism to a historically unshopable market."
They added that the near-term headwinds the company faces are in its "core prescription transaction segment (namely the Kroger (NYSE:KR) renegotiation coupled with increased competitive intensity)."
However, the Citi analysts do not think these headwinds are existential threats and will "instead manifest in slowing revenue growth and moderating EBITDA margin."
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.